Sugi Predict

Sugi Predict / Compounds / SCHEMBL2414928

SCHEMBL2414928

SCHEMBL2414928

O=S(=O)(c1ccc(B(O)O)cc1)C1CC1

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ENPP2 Q13822 3/20 0.53
▸ HTR2A P28223 4/20 0.40
▸ MMP13 P45452 1/20 0.39
▸ KCNH2 Q12809 3/20 0.38
▸ HTR2C P28335 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ CA2 P00918 2/20 0.37
▸ CA1 P00915 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ LPL P06858 1/20 0.37
▸ LIPG Q9Y5X9 1/20 0.37
▸ MAPT P10636 1/20 0.36
▸ AKR1C3 P42330 1/20 0.36
▸ DDIT3 P35638 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29952678 0.91 ENPP2 (0.48) ENPP2HTR2AMMP13KCNH2HTR2C
SCHEMBL29952232 0.88 ENPP2 (0.46) ENPP2HTR2AKCNH2HTR2CTSHR
SCHEMBL19099399 0.85 ENPP2 (0.41) ENPP2HTR2AMMP13KCNH2HTR2C
SCHEMBL22870018 0.80 ENPP2 (0.50) ENPP2HTR2AKCNH2HTR2CCA2
SCHEMBL1526272 0.79 ENPP2 (0.42) ENPP2HTR2AKCNH2KDM4EAKR1C3
SCHEMBL16093162 0.79 APLNR (0.44) ENPP2MMP13
SCHEMBL518863 0.77 LMNA (0.50) ENPP2HTR2AMMP13KCNH2HTR2C
SCHEMBL31713765 0.77 ALDH1A1 (0.46) HTR2AMMP13KCNH2HTR2CMAPT
SCHEMBL2048495 0.76 HTR2A (0.59) HTR2AMMP13KCNH2HTR2CCA2
SCHEMBL28159850 0.76 MMP13 (0.46) HTR2AMMP13KCNH2HTR2CDDIT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026742-A1 COMPOUND AS ATR KINASE INHIBITOR SUZHOU ARK BIOPHARMACEUTICAL CO., LTD. (CN) 2025-01-23 — — US disclosed
CN-115703768-B Compounds useful as inhibitors of ATR kinase 苏州爱科百发生物医药技术有限公司 2024-12-17 — — CN disclosed
US-20240343704-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2024-10-17 — — US disclosed
WO-2024153244-A1 NITROGEN-CONTAINING COMPOUND 南京再明医药有限公司 2024-07-25 — — WO disclosed
US-20240174683-A1 MAP4K1 INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2024-05-30 — — US disclosed
CN-117794924-A Compounds useful as inhibitors of ATR kinase 苏州爱科百发生物医药技术有限公司 2024-03-29 — — CN disclosed
EP-4288437-A1 MAP4K1 INHIBITORS Bayer Aktiengesellschaft (DE) 2023-12-13 — — EP disclosed
WO-2023134629-A1 NUCLEAR TRANSPORT REGULATOR AND USE THEREOF 上海海雁医药科技有限公司 2023-07-20 — — WO disclosed
CN-115703768-A Compounds useful as inhibitors of ATR kinase 苏州爱科百发生物医药技术有限公司 2023-02-17 — — CN disclosed
WO-2023016525-A1 COMPOUND AS ATR KINASE INHIBITOR 苏州爱科百发生物医药技术有限公司 2023-02-16 — — WO disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 — — US disclosed
WO-2022167627-A1 MAP4K1 INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2022-08-11 — — WO disclosed
EP-2964635-B1 ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2018-05-02 — — EP disclosed
US-9693997-B2 Antiviral compounds HOFFMANN-LA ROCHE INC. (US) 2017-07-04 — — US disclosed
US-20160000760-A1 ANTIVIRAL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2016-01-07 — — US disclosed
WO-2014179496-A1 SERINE/THREONINE KINASE INHIBITORS AFRAXIS HOLDINGS, INC. (US) 2014-11-06 — — WO disclosed
US-20140323478-A1 SERINE/THREONINE KINASE INHIBITORS AFRAXIS HOLDINGS, INC. (US) 2014-10-30 — — US disclosed
US-8822503-B2 2-pyridone compounds TAISHO PHARMACEUTICAL CO., LTD (JP) 2014-09-02 — — US disclosed
EP-2508513-A1 2-PYRIDONE COMPOUNDS Taisho Pharmaceutical Co., Ltd. (JP) 2012-10-10 — — EP disclosed
US-20110237791-A1 2-PYRIDONE COMPOUNDS TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-09-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323478-A1 SERINE/THREONINE KINASE INHIBITORS PAK1, PAK2, AKT1 ENPP2 1321/4885HTR2A 3830/4885MMP13 3441/4885
US-20250026742-A1 COMPOUND AS ATR KINASE INHIBITOR ATR, CHEK2, CHEK1 ENPP2 3443/4885HTR2A 4580/4885MMP13 4810/4885
US-20110237791-A1 2-PYRIDONE COMPOUNDS PDXK, HK1, KCNJ2 ENPP2 2387/4885HTR2A 1838/4885MMP13 4302/4885
US-20240174683-A1 MAP4K1 INHIBITORS MAP3K4, MAP4K4, MAP4K1 ENPP2 522/4885HTR2A 4616/4885MMP13 4309/4885
US-20160000760-A1 ANTIVIRAL COMPOUNDS HAVCR2, EIF2AK2, MAVS ENPP2 3058/4885HTR2A 4323/4885MMP13 3104/4885
US-20240343704-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) CMPK1, WNK1, AAK1 ENPP2 2545/4885HTR2A 4364/4885MMP13 4071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.